Conclusion

The author concludes that “endotyping patients with severe asthma with links to pathophysiological mechanisms will lead to a more precise and rational way of getting specific treatments to the individual patients,” which signifies a further “step toward personalized medicine.”


Continue Reading

References


1. Centers for Disease Control and Prevention. Asthma. (2013) Available at: http://www.cdc.gov/nchs/fastats/asthma.htm. Accessed: October 27, 2013.

2. Global Initiative for Asthma (GINA). Pocket Guide for Asthma Management and Prevention. (2012) Available at: http://www.ginasthma.org/local/uploads/files/GINA_Pocket2013_May15.pdf. Accessed: October 27, 2013.

3. American Thoracic Society (ATS). Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. Am J Respir Crit Care Med. 2000;162(6):2341-2351.

4. Chung KF. New treatments for severe treatment-resistant asthma: targeting the right patient. Lancet Respir Med. 2013;1(8):639-652.

5. Lötvall J, Akdis CA, Bacharier LB, et al. Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. J Allergy Clin Immunol.2011;127(2):355-360.

6. McGrath KW, Icitovic N, Boushey HA, et al. A large subgroup of mild-to-moderate asthma is persistently noneosinophilic. Am J Respir Crit Care Med. 2012;185(6):612-619.

7. Woodruff PG, Modrek B, Choy DF, et al. T-helper type 2-drivn inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med. 2009;180(5):388-395.

8. Wenzel SE, Schwartz LB, Langmack EL, et al. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med. 1999;160(3):1001-1018.

9. Jatakanon A, Uasuf C, Maziak W, et al. Neutrophilic inflammation in severe persistent asthma. Am J Respir Crit Care Med. 1999;160(5 Pt 1):1532-1539.

10. Sorkness RL, Bleecker ER, Busse WW, et al. Lung function in adults with stable but severe asthma: air trapping and incomplete reversal of obstruction with bronchodilation. J Appl Physiol. 2008;104(2):394-403.

11. Corren J, Lemanske RF, Hanania NA, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med. 2011;365(12):1088-1098.

12. Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med. 2009;360(10):973-984.